Pharma company fails to block €140m licence payment

Taiwanese pharmaceutical company PharmaEssentia Corporation (PEC) has failed to convince a district court judge to throw out a €140 million award to AOP Orphan Pharmaceuticals (AOP).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Biogen blocking bid rejected; signs $2.4bn deal

28 February 2020 The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.

Americas

Amgen successfully blocks sale of Sandoz’s Zarxio biosimilar

7 May 2015 The US Court of Appeals for the Federal Circuit has blocked US sales of Sandoz’s Zarxio, the biosimilar version of Amgen’s Neupogen, an injection used to prevent infection in patients undergoing chemotherapy.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Pharma company fails to block €140m licence payment

More on this story

Editor's picks

Editor's picks

More features